ID

29003

Beschreibung

A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) given as a booster at 18-24 months of age to pre-term children who have received a three-dose primary immunization course with the same vaccine in study 217744/090.

Stichworte

Versionen (1)
  1. 20.02.18 20.02.18 -
Rechteinhaber

GlaxoSmithKline (GSK)

Hochgeladen am

20. Februar 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) Study ID: 101518

Englisch

Visit 1 Eligibility Check

2 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
Beschreibung

Compliance of Child

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0008059
A male or female 18-24 months of age at the time of the booster vaccination.
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
Subjects must have completed full three-dose primary vaccination course with InfanrixTMhexa in the study 217744/090 (DTPa-HBV-IPV-090).
Beschreibung

undefined item

Datentyp

text

Written informed consent obtained from the parent or guardian of the subject before study entry.
Beschreibung

Informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Free of obvious health problems as established by medical history and clinical examination before entering into the study
Beschreibung

Comorbidity, Medical history

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0009488
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the booster vaccination, or planned use during the study period.
Beschreibung

other medication during study

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C2347852
Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination since the study conclusion visit of study DTPa-HBV-IPV-090.
Beschreibung

Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib

Datentyp

boolean

Alias
UMLS CUI [1]
C0121772
UMLS CUI [2]
C0012546
UMLS CUI [3]
C0039614
UMLS CUI [4]
C0043167
UMLS CUI [5]
C0032371
Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease.
Beschreibung

Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0121772
UMLS CUI [2]
C0012546
UMLS CUI [3]
C0039614
UMLS CUI [4]
C0043167
UMLS CUI [5]
C0032371
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
Beschreibung

immunosuppressive or immunodeficient condition, HIV

Datentyp

boolean

Alias
UMLS CUI [1]
C0021079
UMLS CUI [2]
C0021051
UMLS CUI [3]
C0019682
Planned administration/ administration of a vaccine not foreseen by the study protocol within the 30 days preceding the booster dose.
Beschreibung

other vaccine

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2368628
UMLS CUI [1,2]
C1444655
UMLS CUI [1,3]
C2348563
(Planned) administration of immunoglobulins and/or any blood products during the study period starting 3 months before and ending 30 days after the booster vaccination.
Beschreibung

immunoglobulins and/or any blood products

Datentyp

boolean

Alias
UMLS CUI [1]
C0021027
UMLS CUI [2]
C0456388
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Beschreibung

immunosuppressants or other immune-modifying drugs

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205191
UMLS CUI [2,1]
C0005525
UMLS CUI [2,2]
C0205191
History of seizures (subjects who have had a single, uncomplicated febrile convulsion in the past can be included) or progressive neurological disease.
Beschreibung

Seizures or progressive neurological disease

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0027765
UMLS CUI [1,2]
C1335499
UMLS CUI [2]
C0036572
Major congenital defects or serious chronic illness.
Beschreibung

Major congenital defects or serious chronic illness.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0000768
UMLS CUI [1,2]
C0205164
UMLS CUI [2,1]
C0008679
UMLS CUI [2,2]
C0205404
Acute febrile illness (axillary temperature of ! 37.5°) at the time of planned vaccination (warrants deferral of the vaccination pending recovery of the subject).
Beschreibung

Acute febrile illness

Datentyp

boolean

Alias
UMLS CUI [1]
C0743842
History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
Beschreibung

medical history of hypersensitivity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0020517
Any of the following adverse events having occurred after previous administration of DTP vaccine constitute a contraindication to the administration of the vaccine: - Hypersensitivity reaction due to the vaccine. - Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours. - Fever ! 40 °C (axillary temperature) within 48 hours of vaccination. - Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination. - Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
Beschreibung

former adverse reactions to DTP vaccine

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012559
UMLS CUI [1,2]
C0559546
UMLS CUI [2,1]
C0012559
UMLS CUI [2,2]
C1301624
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Visit 1 Eligibility Check

2 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI-1)
Compliance of Child
Item
Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
boolean
C1321605 (UMLS CUI [1,1])
C0008059 (UMLS CUI [1,2])
Age
Item
A male or female 18-24 months of age at the time of the booster vaccination.
boolean
C0001779 (UMLS CUI [1])
undefined item
Item
Subjects must have completed full three-dose primary vaccination course with InfanrixTMhexa in the study 217744/090 (DTPa-HBV-IPV-090).
text
Informed consent
Item
Written informed consent obtained from the parent or guardian of the subject before study entry.
boolean
C0021430 (UMLS CUI [1])
Comorbidity, Medical history
Item
Free of obvious health problems as established by medical history and clinical examination before entering into the study
boolean
C0262926 (UMLS CUI [1,1])
C0009488 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI-1)
other medication during study
Item
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the booster vaccination, or planned use during the study period.
boolean
C0013227 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib
Item
Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination since the study conclusion visit of study DTPa-HBV-IPV-090.
boolean
C0121772 (UMLS CUI [1])
C0012546 (UMLS CUI [2])
C0039614 (UMLS CUI [3])
C0043167 (UMLS CUI [4])
C0032371 (UMLS CUI [5])
Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease
Item
Evidence of previous or intercurrent, diphtheria, tetanus, pertussis hepatitis B, polio and/or Hib disease.
boolean
C0121772 (UMLS CUI [1])
C0012546 (UMLS CUI [2])
C0039614 (UMLS CUI [3])
C0043167 (UMLS CUI [4])
C0032371 (UMLS CUI [5])
immunosuppressive or immunodeficient condition, HIV
Item
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
boolean
C0021079 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
C0019682 (UMLS CUI [3])
other vaccine
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol within the 30 days preceding the booster dose.
boolean
C2368628 (UMLS CUI [1,1])
C1444655 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,3])
immunoglobulins and/or any blood products
Item
(Planned) administration of immunoglobulins and/or any blood products during the study period starting 3 months before and ending 30 days after the booster vaccination.
boolean
C0021027 (UMLS CUI [1])
C0456388 (UMLS CUI [2])
immunosuppressants or other immune-modifying drugs
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0005525 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
Seizures or progressive neurological disease
Item
History of seizures (subjects who have had a single, uncomplicated febrile convulsion in the past can be included) or progressive neurological disease.
boolean
C0027765 (UMLS CUI [1,1])
C1335499 (UMLS CUI [1,2])
C0036572 (UMLS CUI [2])
Major congenital defects or serious chronic illness.
Item
Major congenital defects or serious chronic illness.
boolean
C0000768 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0008679 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Acute febrile illness
Item
Acute febrile illness (axillary temperature of ! 37.5°) at the time of planned vaccination (warrants deferral of the vaccination pending recovery of the subject).
boolean
C0743842 (UMLS CUI [1])
medical history of hypersensitivity
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
boolean
C0262926 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
former adverse reactions to DTP vaccine
Item
Any of the following adverse events having occurred after previous administration of DTP vaccine constitute a contraindication to the administration of the vaccine: - Hypersensitivity reaction due to the vaccine. - Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours. - Fever ! 40 °C (axillary temperature) within 48 hours of vaccination. - Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination. - Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
boolean
C0012559 (UMLS CUI [1,1])
C0559546 (UMLS CUI [1,2])
C0012559 (UMLS CUI [2,1])
C1301624 (UMLS CUI [2,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video